The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
Abstract
The use of adjuvant chemotherapy for postmenopausal patients with early breast cancer remains controversial because the potential benefits in terms of prolongation of disease-free survival (DFS) and overall survival (OS) must be balanced against the toxicity of treatment. Following mastectomy, 463 evaluable postmenopausal women with node-positive breast cancer were randomized to receive either chemoendocrine therapy for 1 year, or endocrine therapy alone for 1 year, or no adjuvant therapy (Ludwig Trial III). At 7-years median follow-up, OS was longer for the chemoendocrine-treated patients compared with controls (P = .04) and compared with the adjuvant endocrine therapy-alone group (P = .08). In order to balance this therapeutic advantage against the toxic effects of treatment, OS time was divided into time with toxicity (TOX), time without symptoms and toxicity (TWiST), and time after systemic relapse (REL). TOX and REL were weighted by coefficients of utility relative to TWiST and the results added to give a period of quality-adjusted survival (Q-TWiST). Benefits measured by Q-TWiST generally favored chemoendocrine therapy. For example, if TOX and REL were both given utility coefficients of 0.5 relative to 1.0 for TWiST, then by 7 years the average Q-TWiST for chemoendocrine therapy was 6.7 months longer than for no-adjuvant therapy (P = .05) and 4.1 months longer than for endocrine therapy alone (P = .20). Quality-adjusted survival analysis is recommended in assessing costs and benefits of toxic adjuvant therapy. In this example, it supports the use of chemoendocrine therapy in postmenopausal node-positive patients for a wide range of relative values assigned to periods with symptoms and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
The Framing of Decisions and the Psychology of Choice
Tversky, A., & Kahneman, D. (1981) · Science · doi:10.1126/science.7455683 · Cited by 18,497
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
On the Elicitation of Preferences for Alternative Therapies
McNeil, B. J., Pauker, S. G., Sox, H. C., & Tversky, A. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205273062103 · Cited by 1,668
(2005) · Integrative Oncology · doi:10.1201/9780203088319-19 · Cited by 1,579
Censored Data and the Bootstrap
Efron, B. (1981) · Journal of the American Statistical Association · doi:10.1080/01621459.1981.10477650 · Cited by 689
Speech and Survival: Tradeoffs between Quality and Quantity of Life in Laryngeal Cancer
McNeil, B. J., Weichselbaum, R., & Pauker, S. G. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110223051704 · Cited by 677
Utility Functions for Life Years and Health Status
Pliskin, J. S., Shepard, D. S., & Weinstein, M. C. (1980) · Operations Research · doi:10.1287/opre.28.1.206 · Cited by 673
Fallacy of the Five-Year Survival in Lung Cancer
McNeil, B. J., Weichselbaum, R., & Pauker, S. G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197812212992506 · Cited by 473
EVALUATION OF QUALITY OF LIFE IN PATIENTS RECEIVING TREATMENT FOR ADVANCED BREAST CANCER
Priestman, T. J., & Baum, M. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92112-7 · Cited by 399
Cited by
Assessment of Quality-of-Life Outcomes
Testa, M. A., & Simonson, D. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603283341306 · Cited by 2,551
Design and Analysis of Quality of Life Studies in Clinical Trials
Fairclough, D. L. (2002) · Chapman & Hall/CRC eBooks · doi:10.1201/9781420035438 · Cited by 461
A review of the use of health status measures in economic evaluation.
Brazier, Deverill, Green, Harper, & Booth (1999) · Health Technology Assessment · doi:10.3310/hta3090 · Cited by 413
Quality-of-life assessment in clinical trials
Gelber, R. D., & Gelber, S. (1995) · Cancer Treatment and Research · doi:10.1007/978-1-4615-2009-2_11 · Cited by 402
Self-citationShrestha, A., Martin, C., Burton, M., Walters, S., Collins, K., & Wyld, L. (2019) · Psycho-Oncology · doi:10.1002/pon.5054 · Cited by 381
Metadata
- Authors
- Goldhirsch, A., Gelber, R. D., Simes, R. J., Glasziou, P., & Coates, A. S.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-01
- Volume
- 7
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2259708582
- Cited by
- 340
- References
- 14
- FWCI
- 75.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. https://app.cochat.ai/papers/10.1200/jco.1989.7.1.36
- The paper
- Goldhirsch, A., Gelber, R. D., Simes, R. J., Glasziou, P., & Coates, A. S. (1989). Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1989.7.1.36
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.